Flare Therapeutics Announces Initiation of Phase 1B Study of FX-909 for Treatment of Metastatic Urothelial Cancer

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Marea Therapeutics Enrolls First Patient in Phase 2b TYDAL-TIMI 78 Clinical Study Evaluating MAR001 in Adults at Risk of ASCVD

ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha Radioligand Therapies and Expand Manufacturing and Supply Chain Infrastructure

MOMA Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial for MOMA-341,a Highly Potent and Selective Werner Helicase Inhibitor